The compositions may appear in conventional forms, for example capsules, tablets, aerosols, solutions, suspensions or topical applications. [0204] Typical compositions include a compound of the invention which inhibits the enzymatic activity of DPP-IV or a pharmaceutically acceptable basic addition salt or prodrug or hydrate thereof, associated with a pharmaceutically acceptable excipient which ma